Breast Cancer: KOL Insight [2017]

LONDON, Aug.8, 2017 /PRNewswire/ -- How is Ibrance faring? Is Kisqali expected to be a threat?Having dominated the HER2-positive breast cancer space for many years, Roche's blockbuster drug Herceptin is likely to face the threat of biosimilar trastuzumab in the coming years; KOLs weigh in...